Kawasaki disease and acute haemolytic anaemia after two IVIG infusions

References

• Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on Rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Circulation. 2004;110:2747–2771.
   PubMed Web of Science ®Google Scholar
• McCrindle BW. Kawasaki disease: a childhood disease with important consequences into adulthood. Circulation. 2009;120:6–8.
   PubMed Web of Science ®Google Scholar
• Michihata N, Matsui H, Fushimi K, et al. Guideline-concordant treatment of Kawasaki disease with immunoglobulin and aspirin and the incidence of coronary artery aneurysm. Clin Pediatr (Phila). 2015;54:1076–1080.
   PubMed Web of Science ®Google Scholar
• Eleftheriou D, Levin M, Shingadia D, et al. Management of Kawasaki disease. Arch Dis Child. 2014;99:74–83
   PubMed Web of Science ®Google Scholar
• Vierucci F, Azzarelli A, Gualtierotti R, et al. Changing management of Kawasaki disease. J Compr Ped [Internet]. 2014 [ cited 2016 Jan 20];5:e19519. Available from: http://dx.doi.org/10.17795/compreped-19519
   Google Scholar
• Kawasaki T. Kawasaki disease. Int J Rheumatol Dis. 2014;17:597–600.
   PubMed Web of Science ®Google Scholar
• Berger M. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep. 2002;2: 368–378.
   PubMedGoogle Scholar
• European Medicines Agency (EMA). KIOVIG: EPAR-scientific discussion [Internet]. London: EMA; c1995–2016 [2006 Mar 22; cited 2016 Feb 8]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000628/WC500043413.pdf.
   Google Scholar
• European Medicines Agency (EMA). European Medicines Agency recommends lifting of suspension of Octagam [Internet]. Recommendation follows implementation of improved manufacturing process and other preventive measures. London: EMA; c1995–2016 [2011 Apr 14; cited 2016 Feb 8]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/04/news_detail_001242.jsp&mid=WC0b01ac058004d5c1.
   Google Scholar
• Palabrica F, Kwong S, Padua F, et al. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. Asia Pac Allergy. 2013;3(4):249–256.
   PubMedGoogle Scholar
• Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child. 2006;91(8):651–654.
   PubMed Web of Science ®Google Scholar
• Berard R, Whittemore B, Scuccimarri R. Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases. Pediatr Rheumatol Online J [Internet]. 2012 [ cited 2016 Jan 20];10:10. Available from: http://dx.doi.org/10.1186/1546-0096-10-10.
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Watanabe N, Okuno M, et al. Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease. Am J Hematol. 2000;63:160–161.
   PubMed Web of Science ®Google Scholar
• Simon HU, Späth PJ. IVIG – mechanisms of action. Allergy. 2003;58(7):543–552.
   PubMed Web of Science ®Google Scholar
• Knezevic-Maramica I, Krauskall M. Intravenous immune globulins: an update for clinicians. Transfusion. 2003;43:1460–1480.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med. 2004;10:17–18.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. The anti-inflammatory activity of IgG: the intravenous IgG paradox. J Exp Med. 2007;204:11–15.
   PubMed Web of Science ®Google Scholar
• Jacob S, Rajabally Y. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol. 2009;7(4):337–342.
   PubMed Web of Science ®Google Scholar
• Ferenčík M. Handbook of immunochemistry. Dodrecht: Springer; 1993. Chapter 8, Preparation of pure immunoglobulins; p. 191–224.
   Google Scholar
• Ballow M. Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol. 2014;14:509–515.
   PubMed Web of Science ®Google Scholar
• Rogers JR, Rich RR. Antigens and antigen presentation. In: Rich RR, editor. Clinical immunology, principles and practice. 4th ed. China: Elsevier/Saunders; 2013. p. 77–89.
   Google Scholar
• Yung TC, LY So, Ho HK, et al. Clinical guideline on the use of intravenous gammaglobulin in children with Kawasaki disease. HK J Paediatr (new series). 2002;7:10–16.
   Google Scholar
• Sherer Y, Levi Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune disease. Pharmacology. 2001;62:133–137.
   PubMed Web of Science ®Google Scholar
• Katz U, Shoenfeld Y. Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus. 2005;14:802–808.
   PubMed Web of Science ®Google Scholar
• Wittstock M, Zettl UK. Adverse effects of treatment with intravenous immunoglobulins for neurological diseases. J Neurol. 2006;253(Suppl 5):V75–V79.
   PubMed Web of Science ®Google Scholar
• Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulines. Clin Exp Immunol. 1994;97(Suppl 1):79–83.
   PubMed Web of Science ®Google Scholar
• Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion. 2008;48:1598–1601.
   PubMed Web of Science ®Google Scholar
• Padmore R. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports. Transfusion. 2015;55(Suppl 2):S59–S64.
   PubMed Web of Science ®Google Scholar
• Kahwaji J, Barker E, Pepkowitz S, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol. 2009;4:1993–1997.
   PubMed Web of Science ®Google Scholar
• Luban NL, Wong EC, Henrich LR, et al. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease. Transfusion. 2015;55(Suppl 2):S90–S94.
   PubMed Web of Science ®Google Scholar
• Pendergrast JM, Pavenski K, Hannach B. Does deficiency of plasma A/B substances increase the risk of IVIG-mediated hemolysis? Transfusion. 2007;47:194A–195A.
   PubMed Web of Science ®Google Scholar
• Shoham-Kessary H, Naot Y, Gershon H. Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes. Clin Exp Immunol. 1998;113:77–84.
   PubMed Web of Science ®Google Scholar